These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C. Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528 [Abstract] [Full Text] [Related]
3. What is the most effective strategy for managing diabetic dyslipidaemia? Reasner CA. Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442 [Abstract] [Full Text] [Related]
4. Management of hypercholesterolaemia in the patient with diabetes. Packard C, Olsson AG. Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606 [Abstract] [Full Text] [Related]
7. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Breuer HW. Curr Med Res Opin; 2001 Dec; 17(1):60-73. PubMed ID: 11464448 [Abstract] [Full Text] [Related]
8. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective. Roze S, Ferrières J, Bruckert E, Van Ganse E, Chapman MJ, Liens D, Renaudin C. Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322 [Abstract] [Full Text] [Related]
9. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE. J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [Abstract] [Full Text] [Related]
15. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. Duvall WL, Blazing MA, Saxena S, Guyton JR. J Cardiovasc Risk; 2002 Dec 18; 9(6):339-47. PubMed ID: 12478203 [Abstract] [Full Text] [Related]
17. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Temelkova-Kurktschiev T, Hanefeld M. Exp Clin Endocrinol Diabetes; 2004 Feb 18; 112(2):75-9. PubMed ID: 15031770 [Abstract] [Full Text] [Related]
18. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Raal FJ. Metab Syndr Relat Disord; 2009 Apr 18; 7(2):83-8. PubMed ID: 19400742 [Abstract] [Full Text] [Related]
19. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Toth PP. Am J Cardiol; 2005 Nov 07; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015 [Abstract] [Full Text] [Related]